Clinical Trial Update: A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and pharmacokinetics of DMUC4064A in platinum-resistant ovarian cancer and unresectable pancreatic cancer has been completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• DMUC4064A

Snippet

Sponsor: Genentech, Inc. | Conditions: Pancreatic Neoplasms, Ovarian Neoplasms | Phase 1 | Status: COMPLETED